|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
SCIDIR_on1147277549 |
| 003 |
OCoLC |
| 005 |
20231120010444.0 |
| 006 |
m o d |
| 007 |
cr un|---aucuu |
| 008 |
200328s2020 enk o 000 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d OPELS
|d OCLCQ
|d UKAHL
|d YDX
|d N$T
|d P4A
|d OCLCF
|d UHL
|d OCLCO
|d VRC
|d OCLCO
|d OCLCQ
|d OCLCO
|d K6U
|d OCL
|d OCLCQ
|d OCLCO
|
| 019 |
|
|
|a 1146574636
|
| 020 |
|
|
|a 0128127856
|
| 020 |
|
|
|a 9780128127858
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128127841
|
| 035 |
|
|
|a (OCoLC)1147277549
|z (OCoLC)1146574636
|
| 050 |
|
4 |
|a QP171
|
| 082 |
0 |
4 |
|a 572/.4
|2 23
|
| 245 |
0 |
0 |
|a Metabolomics for biomedical research /
|c edited by Jerzy Adamski
|
| 260 |
|
|
|a London :
|b Academicv Press,
|c 2020.
|
| 300 |
|
|
|a 1 online resource (268 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Intro -- Metabolomics for Biomedical Research -- Copyright -- Contents -- Contributors -- Preface -- Chapter 1: Introduction to metabolomics -- 1. What is metabolomics? -- 2. Flow chart of metabolomic research -- 2.1. Scientific question -- 2.2. Study design: General aspects -- 2.3. Study design: Pilot study and power calculation -- 2.4. Study design: Sample identity -- 2.5. Study design: Preanalytics -- 2.6. Study design: Sample matrix -- 2.7. Study design: Confounders -- 2.8. Study design: Time schedule -- 2.9. Study design: Randomization -- 2.10. Study design: Budgeting and resources
|
| 505 |
8 |
|
|a 2.11. Study design: Contingency plan -- 2.12. Study design: Legal aspects -- 2.13. Study design: Governance -- 2.14. Study design: Replication -- 2.15. Analytics -- 2.16. Data validation -- 2.17. Data release -- 3. Future trends -- 3.1. Standardization -- 3.2. Coverage and speed -- 3.3. Accessibility -- 3.4. Mechanisms of disease -- 3.5. Biomarkers -- Acknowledgments -- References -- Chapter 2: Confounders in metabolomics -- 1. Introduction to the confounder concept -- 2. Important confounders in metabolomics -- 2.1. Genetic background and ethnicity -- 2.2. Sex -- 2.3. Age -- 2.4. Nutrition
|
| 505 |
8 |
|
|a 3. Body mass index -- 3.1. Physical activity -- 3.2. Alcohol -- 3.3. Smoking -- 3.4. Stress -- 3.5. Circadian rhythm -- 3.6. Hormonal status -- 3.7. Medication -- 3.8. Lifestyle -- 4. Disease -- 5. Consequences for study design -- 6. Future trends -- References -- Chapter 3: Pre-analytics in biomedical metabolomics -- 1. Introduction -- 2. Principles to be considered before the collection of body fluids for biomedical metabolomics -- 2.1. Patients instructions and sophisticated questionaries can avoid outliers -- Points to be considered before sample collection
|
| 505 |
8 |
|
|a Suggestions of choice for additional points in a study questionnaire -- 2.1.1. Control groups: Undiagnosed, asymptomatic diseases of apparently healthy subjects can bias metabolomics findings -- 2.2. Sample collectors for blood and urine in biomedical metabolomics studies -- 2.2.1. Blood collection tubes are potential sources of chemical noise disturbing metabolomics analysis -- 2.2.2. Additives in plasma blood collection tubes which can be used and which should be avoided -- 2.2.3. Additives in serum blood collection tubes may lead to chemical noise
|
| 505 |
8 |
|
|a 2.2.4. Dried blood spot metabolomics: Stability of the detected mixture of metabolites from erythrocytes, leukocytes, thr ... -- 2.2.5. Urine cups and containers: Pretests are imperative to avoid analytical problems -- 2.3. Animal studies: Some pre-analytical characteristics are different from human biomedical metabolomics -- 3. Collection, handling, and storage of body fluids for metabolomics investigations -- 3.1. Blood -- 3.1.1. Handling of whole blood can greatly affect the sample quality and the metabolome of plasma and serum -- Plasma: Time and temperature until plasma separation is crucial
|
| 500 |
|
|
|a Serum: The coagulation process must be tightly controlled
|
| 650 |
|
0 |
|a Metabolites.
|
| 650 |
|
0 |
|a Research.
|
| 650 |
1 |
2 |
|a Medicine
|0 (DNLM)D008511
|
| 650 |
2 |
2 |
|a Research
|0 (DNLM)D012106
|
| 650 |
|
6 |
|a M�etabolites.
|0 (CaQQLa)201-0030193
|
| 650 |
|
6 |
|a Recherche.
|0 (CaQQLa)201-0029424
|
| 650 |
|
7 |
|a research (function)
|2 aat
|0 (CStmoGRI)aat300054687
|
| 650 |
|
7 |
|a Research
|2 fast
|0 (OCoLC)fst01095153
|
| 650 |
|
7 |
|a Metabolites
|2 fast
|0 (OCoLC)fst01017507
|
| 700 |
1 |
|
|a Adamski, Jerzy.
|
| 776 |
0 |
8 |
|i Print version:
|a Adamski, Jerzy.
|t Metabolomics for Biomedical Research.
|d San Diego : Elsevier Science & Technology, �2020
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128127841
|z Texto completo
|
